Voyager Therapeutics, Inc.

Voyager Therapeutics, Inc.

Biotechnology • Healthcare • Lexington, MA, United States • VYGR (NMS)

Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. The company's lead product candidate is VY7523, an anti-tau antibody program for the treatment of alzheimer's disease (AD). Its product pipeline includes VY1706, a tau silencing gene therapy in preclinical trial for the treatment of alzheimer's disease; SOD1 silencing gene therapy program for treating amyotrophic lateral sclerosis in preclinical trial; and vectorized anti-amyloid antibody early research program for the treatment of AD in preclinical trial. The company is also developing VY-FXN01 for treating friedreich's ataxia; and GBA1 gene replacement program to treat parkinson's disease. In addition, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Ireland Limited; Novartis Pharma AG; and Neurocrine Biosciences, Inc. for the treatment of various other diseases of the central nervous system. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.

857 259 5340 75 Hayden Avenue, Lexington, MA 02421, United States

Stock Performance (90 Days)

Data through Dec 29, 2025
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Voyager Therapeutics (VYGR): Strong Q3 Prompts Bullish Coverage - Yahoo Finance
Yahoo Finance • Dec 10
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
MarketBeat • Dec 27
Voyager Therapeutics stock price target raised to $12 by Leerink Partners - Investing.com
Investing.com • Nov 10
Voyager Reports Third Quarter 2025 Financial and Operating Results - GlobeNewswire
GlobeNewswire • Nov 10
7 Analysts Assess Voyager Therapeutics: What You Need To Know - Nasdaq
Nasdaq • Apr 8

Other Biotechnology Companies

View All →
CODEXIS, INC. logo Codexis, Inc.
1 layoff tracked
$144.5M market cap
VERTEX PHARMACEUTICALS INC / MA logo Vertex Pharmaceuticals Inc. / MA
$118.68B market cap
REGENERON PHARMACEUTICALS, INC. logo Regeneron Pharmaceuticals, Inc.
$82.72B market cap
ALNYLAM PHARMACEUTICALS, INC. logo Alnylam Pharmaceuticals, Inc.
$52.92B market cap
ARGENX SE logo Argenx SE
$52.62B market cap
INSMED Inc logo Insmed Inc.
$37.61B market cap

Frequently Asked Questions

Has Voyager Therapeutics, Inc. had layoffs?
No layoff events have been recorded for Voyager Therapeutics, Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
How many employees does Voyager Therapeutics, Inc. have?
Voyager Therapeutics, Inc. has approximately 172 employees.
What industry is Voyager Therapeutics, Inc. in?
Voyager Therapeutics, Inc. operates in the Biotechnology industry, within the Healthcare sector.
Is Voyager Therapeutics, Inc. a publicly traded company?
Yes, Voyager Therapeutics, Inc. is publicly traded under the ticker symbol VYGR on the NMS. The company has a market capitalization of approximately $0.22 billion.
Where is Voyager Therapeutics, Inc. headquartered?
Voyager Therapeutics, Inc. is headquartered in Lexington, MA, United States at 75 Hayden Avenue, Lexington, MA 02421, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.